| Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High? |
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-15 15:00:39 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript) |
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ET Company Participants Ed Dulac - CFO Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Hello, everyone. Thanks for joining the session with Intellia Therapeutics on day 1 of the 2025 Bank of America Healthcare Conference. |
seekingalpha.com |
2025-05-14 17:57:08 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade) |
Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test results that were fine with medical experts and the FDA. The Street hated when NTLA dropped a lesser program and laid off some staff members. On 5/8/25, the Company reported further progress with two treatments that are now ensconced in Phase III of testing—a level only a third of new drugs reach. |
seekingalpha.com |
2025-05-12 13:07:07 |
Czytaj oryginał (ang.) |
| Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up |
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. |
zacks.com |
2025-05-09 17:25:46 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript |
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President and Chief Executive Officer David Lebwohl - Chief Medical Officer Ed Dulac - Executive Vice President and Chief Financial Officer Birgit Schultes - Executive Vice President and Chief Scientific Officer Conference Call Participants Gena Wang - Barclays Kostas Biliouris - BMO Capital Markets Luca Issi - RBC Maury Raycroft - Jefferies Mitchell Kapoor - H. C. Wainwright Jay Olson - Oppenheimer Rick Bienkowski - Cantor Fitzgerald Yanan Zhu - Wells Fargo Troy Langford - TD Cowen Jake Roberge - William Blair Brian Cheng - JPMorgan William Pickering - Bernstein David Lebowitz - Citi Operator Good morning, and welcome to Intellia' First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-08 15:37:08 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates |
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago. |
zacks.com |
2025-05-08 13:51:00 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an inducement grant to eight new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. |
globenewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts |
Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better positioned to navigate near-term challenges with a strong cash reserve and upcoming product launches, justifying an upgrade to 'Strong Buy.' NTLA, despite promising product candidates, faces higher risks and requires significant cost reductions to extend its cash runway, maintaining a "Buy" rating for high-risk investors. |
seekingalpha.com |
2025-05-05 08:44:56 |
Czytaj oryginał (ang.) |
| Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline |
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:06:50 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average |
Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA broke out above the 50-day moving average, suggesting a short-term bullish trend. |
zacks.com |
2025-05-01 14:30:49 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates |
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. |
globenewswire.com |
2025-05-01 11:30:00 |
Czytaj oryginał (ang.) |
| Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought |
Cathie Wood's investing style is bouncing back into fancy. The co-founder, CEO, and investment manager of Ark Invest is winning again. |
fool.com |
2025-04-30 14:15:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-29 14:55:39 |
Czytaj oryginał (ang.) |
| Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation |
SAN DIEGO , April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of those NASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. |
prnewswire.com |
2025-04-23 13:50:00 |
Czytaj oryginał (ang.) |
| Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA |
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=143015&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-14 21:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA |
NEW YORK , April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
prnewswire.com |
2025-04-14 20:14:00 |
Czytaj oryginał (ang.) |
| NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) and certain of its officers. |
globenewswire.com |
2025-04-14 20:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Lawsuit - NTLA |
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=142988&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-14 18:00:00 |
Czytaj oryginał (ang.) |
| NTLA DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA |
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
accessnewswire.com |
2025-04-14 17:30:00 |
Czytaj oryginał (ang.) |
| NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm |
LOS ANGELES--(BUSINESS WIRE)--NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm. |
businesswire.com |
2025-04-14 15:35:00 |
Czytaj oryginał (ang.) |
| Intellia Crashes 60% in a Year: How Should You Play the Stock? |
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now. |
zacks.com |
2024-12-20 16:00:33 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2024, it awarded an inducement grant to one new employee under Intellia's 2024 Inducement Plan as a material inducement to employment. |
globenewswire.com |
2024-12-03 18:01:00 |
Czytaj oryginał (ang.) |
| NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy |
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy. |
zacks.com |
2024-11-26 13:30:41 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy |
CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an in vivo CRISPR-based investigational therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron. |
globenewswire.com |
2024-11-25 09:30:00 |
Czytaj oryginał (ang.) |
| Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? |
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? |
fool.com |
2024-11-22 10:30:00 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade) |
Intellia initiated the Phase 3 HAELO trial for NTLA-2002, targeting lifelong control of hereditary angioedema (HAE) with a single-dose CRISPR-based therapy. Positive Phase 2 NTLA-2002 data showed most patients remained attack-free; however, limitations like small sample size and short follow-up require cautious interpretation. Phase 1 data for nexiguran ziclumeran (nex-z) in ATTR amyloidosis showed disease stabilization, but competitive therapies demonstrate more robust improvements. |
seekingalpha.com |
2024-11-19 00:57:49 |
Czytaj oryginał (ang.) |
| Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis |
CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z, also known as NTLA-2001) in patients with transthyretin (ATTR) amyloidosis. Nex-z is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron. |
globenewswire.com |
2024-11-16 12:16:00 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus |
Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month's drop is appropriately discounting NTLA-2002, investors should be encouraged that 3 Phase III trials will be engaged by year-end, representing multiple opportunities for substantial upside. Intellia's financial position is robust with $945 million in cash, enough to fund operations into late 2026. |
seekingalpha.com |
2024-11-11 10:30:00 |
Czytaj oryginał (ang.) |
| 3 Fast-Growing Stocks Analysts See Doubling in Price |
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise. |
marketbeat.com |
2024-11-11 09:16:18 |
Czytaj oryginał (ang.) |
| NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus |
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates. |
zacks.com |
2024-11-08 12:50:18 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript |
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Lina Li - Senior Director of Investor Relations and Corporate Communications John Leonard - President & Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer Ed Dulac - Executive Vice President & Chief Financial Officer Conference Call Participants Rick Bienkowski - Cantor Fitzgerald Yanan Zhu - Wells Fargo Securities Joseph Thome - TD Cowen Maury Raycroft - Jefferies Dae Gon Ha - Stifel Jay Olson - Oppenheimer Silvan Tuerkcan - Citizens JMP William Pickering - Bernstein Operator Good morning and welcome to Intellia Therapeutics' Third Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today. |
seekingalpha.com |
2024-11-07 16:49:06 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates |
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $1.38 per share a year ago. |
zacks.com |
2024-11-07 11:56:27 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress |
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-11-07 09:30:00 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? |
There's nothing bearish at all about what it reported recently. |
fool.com |
2024-11-06 11:45:00 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on November 1, 2024 it awarded inducement grants to ten new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. |
globenewswire.com |
2024-11-05 18:01:00 |
Czytaj oryginał (ang.) |
| This Beaten-Down Stock Could Soar by 354%, According to Wall Street |
Maybe the Street is a bit too optimistic on this one. |
fool.com |
2024-11-04 10:00:00 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 |
CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November. |
globenewswire.com |
2024-10-31 09:30:00 |
Czytaj oryginał (ang.) |
| 12 High-Growth Stocks That Could Deliver Parabolic Returns |
These 12 innovative companies could deliver exponential returns over the next quarter century. |
fool.com |
2024-10-28 12:00:00 |
Czytaj oryginał (ang.) |
| Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity |
Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week primary observation period. Despite the stock price trading lower by 20%, the HAE treatment program continues on using NTLA-2002 in the phase 3 HAELO study. The global hereditary angioedema treatment market size is projected to reach $17.31 billion by the end of 2032. |
seekingalpha.com |
2024-10-25 16:25:58 |
Czytaj oryginał (ang.) |
| Why Intellia Therapeutics Stock Plummeted by 20% Today |
Seemingly encouraging results from the lab were met with some notable skepticism. |
fool.com |
2024-10-24 23:22:00 |
Czytaj oryginał (ang.) |